Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

265P - UCATS: A national specialist service for integration of gender affirming and oncological care in transgender patients with breast cancer

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Alison Berner

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101224-101224. 10.1016/esmoop/esmoop101224

Authors

A.M. Berner1, S. O'Callaghan2, F. Lander3, M.D. Bower3

Author affiliations

  • 1 Cancer Research UK Barts Centre - Queen Mary University of London, London/GB
  • 2 Live Through This, London/GB
  • 3 Chelsea and Westminster Hospital - NHS Trust, London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 265P

Background

The transgender population face inequalities throughout the cancer pathway. Much of this stems from a lack of access to specialist knowledge of gender-affirming care and how it intersects with cancer. Breast cancer care in particular presents challenges for both patients and clinicians given the interaction with sex hormones , potential to exacerbate dysphoria and differing management in cisgender men vs. cisgender women. Breast cancer risk remains of concern in trans people. The best estimate of breast cancer incidence is trans men and non-binary people assigned female at birth (TMNB) is only 5 times less than in cisgender women. In trans women and non-binary people assigned male at birth (TFNB) the incidence is only 3 times less than in cisgender women. However cancer registries in most countries fail to accurately record gender identity and trans status.

Methods

In response to this need, we established the UK Cancer and Transition Service (UCATS), a national multidisciplinary team meeting and clinic where any transgender patient with active or historical cancer can access specialist advice and support. This was coproduced with patient and public involvement and input from a specialist cancer charity.

Results

We discuss 6 cases of breast cancer in TMNB where cancer and gender-affirming care were mutually impacted by each other. Two of these lead to the establishment of UCATS and a further 4 were managed by the service. Challenges experienced by patients and clinicians included access to satisfactory reconstructive options, access to and management of gender-affirming hormones, and choice of anti-oestrogenic therapy.

Conclusions

We recommend introduction similar services internationally and inclusion of gender identity and trans status in cancer registries to improve data collection on cancer risk. Further research is required on the use of gender-affirming hormones in hormone receptor-positive breast cancer in adjuvant and metastatic settings.

Legal entity responsible for the study

Chelsea and Westminster Hospitals NHS Trust.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.